AVALO THERAPEUTICS, INC. (AVTX) Operating income 2016–2025
AVALO THERAPEUTICS, INC. (AVTX) annual operating income history from SEC filings — each fiscal year as reported.
-$72.9MFY2025 · since FY2016: -$16.1M → -$72.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$72.9M | -6.4% |
| FY2024 | -$68.5M | -150.5% |
| FY2023 | -$27.4M | +26.9% |
| FY2022 | -$37.4M | +54.4% |
| FY2021 | -$82.1M | -12.8% |
| FY2020 | -$72.8M | -351.4% |
| FY2019 | -$16.1M | +54.4% |
| FY2018 | -$35.4M | -354.7% |
| FY2017 | $13.9M | +186.4% |
| FY2016 | -$16.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating marginAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →